Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harvoni in Pediatric HCV
NCT02249182Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of ledipasvir in hepatitis C (HCV) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Area Under the Concentration-Time Curve Over the Dosing Interval at Day 10 and Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event at 24 weeks. Started Nov 2014; status: completed.
02
Drugs
ledipasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02249182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249182.